Loopbaan van John Fry
Eerdere bekende functies van John Fry
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-09-2018 | 01-04-2023 |
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Hoofd Techniek/Wetenschap/O&O | 01-02-2012 | 01-11-2014 |
| Corporate Officer/Principal | 01-11-2014 | 01-08-2018 |
Opleiding van John Fry
| University of Sussex | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 3 |
| Verenigd Koninkrijk | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
